The discovery of groundbreaking medical treatments may no longer solely rest in the hands of scientists; grassroots R&D efforts combine scientific expertise with the experiences and creativity and horsepower of the masses.
After the boom of Blockbuster(drugs with revenues exceeding $1B/yr) approvals in the 90’s, there has been a slowdown in the development of new drug entities (NDE). With drugs already in the market for easy to identify targets, research in academia […]
Faced with increased price and regulatory pressures, the pharma industry is forced to look to other avenues for revenue growth, including digitilization of its historically unwieldy and heavily regulated supply chains. Is industry leader Pfizer doing enough in this pursuit?
It’s hard to tell whether the lack of innovation in the healthcare industry has been driven by heightened regulation or risk-adverse corporations, but one thing is certain: Industry leaders like Pfizer must start to embrace digitalization or risk losing some of their competitive advantages.
How the "Internet of Things" is impacting the pharma industry
Counterfeit drugs adversely impact both consumers and pharmaceutical companies. Can blockchain help solve this problem?
Finding growth, repositioning the business and being nimble in the dynamic pharma environment
